Thirteen Years' Experience of Pharmacokinetic Monitoring and Dosing of Busulfan: Can the Strategy be Improved?

@article{Buffery2014ThirteenYE,
  title={Thirteen Years' Experience of Pharmacokinetic Monitoring and Dosing of Busulfan: Can the Strategy be Improved?},
  author={Pamela J Buffery and Kirstie M Allen and P. Chin and G. Moore and M. Barclay and E. Begg},
  journal={Therapeutic Drug Monitoring},
  year={2014},
  volume={36},
  pages={86–92}
}
Background: A busulfan concentration monitoring and dosing service has been provided by Christchurch Hospital since 1998. This study aimed to see (1) the percentage of patients with an area under the concentration time curve (AUC) outside the target range and had dose adjustment, (2) how busulfan clearance (CL) relates to body weight, and (3) if fewer samples could be used to predict doses. Methods: Blood samples were taken from patients after oral administration, usually at 0.5, 1, 1.5, and 6… Expand
Limited Sampling Strategies Supporting Individualized Dose Adjustment of Intravenous Busulfan in Children and Young Adults.
TLDR
MLR-based estimates of AUCLSS provide dose adjustment recommendations (DARs) that deviate minimally from the reference and may encourage wider use of busulfan TDM, supporting safe and efficacious personalized dosing. Expand
Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2‐ and 6‐Hour Blood Sampling in Adult Patients Receiving a Twice‐Daily Intravenous Busulfan‐Based Conditioning Regimen
TLDR
A test dose with a 2‐sampling scheme was sufficient to personalize the initial busulfan dosing in hematopoietic cell transplant recipients, and the Bland‐Altman plot showed that the 2‐Sampling scheme provided an acceptably accurate prediction of the AUC1. Expand
Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.
TLDR
A significant improvement in target AUC attainment and less interpatient variability with PK-guided dosing using a test dose strategy compared with weight-based dosing is demonstrated. Expand
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide
TLDR
The BuCy/PTCy platform has a low incidence of treatment-related toxicity, including hepatotoxicity, in hematologic malignancies when using pharmacokinetics for a target AUC of 800–1400 μmol*min/L, irrespective of Bu administration route. Expand
Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
  • J. Zao, T. Schechter, +5 authors L. Dupuis
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2015
TLDR
The authors' objective was to describe the AUCs achieved after simulated dosing using available pediatric i.v. busulfan dosing guidelines, and recommend 1 of 3 high-performing guidelines that allow individualization of the targetBusulfan AUC. Expand
Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children
TLDR
Therapeutic drug monitoring (TDM)-guided dosing to reach the conventional area under the concentration–time curve (AUC) target range of 900–1500 μmol min/L is associated with better outcomes and busulfan TDM combined with model-based dose adjustment was associated with an increased probability of AUC target attainment. Expand
Limited sampling strategy for predicting busulfan exposure in hematopoietic stem cell transplantation recipients
TLDR
The 2-sample model is an effective and reliable approach to predict the AUC0-12 of twice-daily intravenous busulfan in Chinese adult patients. Expand
A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics
TLDR
The approach can be applied for OPT dosing of many drugs, when the target objective is an interval, and outperformed the traditional model-based dosing approach, with earlier and better achievement of busulfan target AUC. Expand
Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children
TLDR
Significant busulfan intra-individual variability may occur in children who receive a HSCT and is hardly predictable, so performing TDM repeatedly over therapy appears to be the best way to accurately estimateBusulfan exposure and perform precision dosing. Expand
Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation
TLDR
Most of the authors' patients had less than a proportional increase in busulfan concentration suggesting autoinduction, and recommended doses were adequate for most patient groups, except those in the lower (< 9 kg) and higher weight groups (> 34 kg). Expand
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Plasma concentration monitoring of busulfan: does it improve clinical outcome?
TLDR
Therapeutic drug monitoring of busulfan should be performed to maximise the likelihood of engraftment and minimise the risk of toxicity and relapse in HSCT patients receiving the BU/CY preparative regimen. Expand
Population Pharmacokinetic–Based Dosing of Intravenous Busulfan in Pediatric Patients
TLDR
The objective of this study was to characterize the pharmacokinetics of intravenous busulfan in pediatric patients and provide dosing recommendations and Therapeutic drug monitoring and dose adjustment to improve therapeutic targeting. Expand
A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.
TLDR
It is validated that LSS for IV busulfan will make possible meaningful and accurate comparisons ofBusulfan versus TBI-based preparative regimens and comparison of dose intensity of bus sulfuran-containing preparativeregimens in trials of submyeloablative transplantation. Expand
Development of a Population Pharmacokinetics‐Based Sampling Schedule to Target Daily Intravenous Busulfan for Outpatient Clinic Administration
TLDR
The optimal 6‐hour outpatient sampling schedule was constructed using a simulation approach that sought to minimize scaled mean squared error for the clearance and volume parameters for each simulated individual and the maximum a posteriori (MAP) Bayesian estimation was superior to maximum likelihood estimation with more samples. Expand
Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes
TLDR
It is concluded that intravenous busulfan in children administered once daily is safe, convenient and feasible, and can be dosed surface-based, independent of age. Expand
Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity
TLDR
It is concluded that, in accordance with previous data, within the observed AUCs no clear relationship was observed between Bu AUC and outcome with respect to toxicity, engraftment and relapse. Expand
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
TLDR
A limited sampling strategy based on a Bayesian methodology was developed and validated on an independent dataset: AUCs obtained from one to two samplings were demonstrated to be reliably estimated and no dose adjustment is required in obese patients when using a AIBW- or BSA-based dose calculation. Expand
I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients
TLDR
A retrospective population pharmacokinetic analysis was performed in 24 pediatric patients (PEDS) receiving i.v. Bu prior to allogeneic hematopoietic stem cell transplantation, and age-based dosing was demonstrated not to be clinically relevant with i.V. Bu. Expand
Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring.
TLDR
Administration of single daily doses of Bu has been shown to be safe and effective with oral Bu and has been used with i.v. preparations, and provides the possibility of defining a target exposure level associated with a good outcome. Expand
Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients
TLDR
The model-based individual dosing nomogram is expected to result in predictive busulfan exposures in patients ranging between 3 and 65 kg and thereby to a safer and more effective conditioning regimen for HSCT in children. Expand
...
1
2
...